Good evening :)
Switch to
Place Order

Lupin Ltd

LUPIN
Health CarePharmaceuticals
MidcapWith a market cap of ₹43,577 cr, stock is ranked 116
Low RiskStock is 1.92x as volatile as Nifty
939.5019.95 (-2.08%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
MidcapWith a market cap of ₹43,577 cr, stock is ranked 116
Low RiskStock is 1.92x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
35.82
PB RatioPB Ratio
3.14
Dividend YieldDiv. Yield
0.68%
Sector PESector PE
38.40
Sector PBSector PB
5.11
Sector Div YldSctr Div Yld
0.67%

Forecast & RatingsDetailed Forecast 

49%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Lupin Limited is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world.

Brands

Lupin

Pharmaceutical company

Investor PresentationView older 

Jan 12, 2022

PDF
View Older Presentations

Brands

Lupin

Pharmaceutical company

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Financial TrendFinancial statements 

201820192020202115.9515.1015.9915.300.250.61-0.271.22
Revenue
Profit
Loss
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Press Release 
Announced OnJan 19, 2022

Lupin Limited has informed the Exchange regarding a press release dated January 19, 2022, titled "Lupin Signs First Partnership Agreement with Foncoo for China". | Download

Lupin Limited has informed the Exchange regarding a press release dated January 19, 2022, titled "Lupin Signs First Partnership Agreement with Foncoo for China". | Download

Acquisition 
Announced OnJan 18, 2022

Lupin Limited has informed the Exchange about acquisition of a portfolio of brands (including all rights and interests associated with such products) of Anglo-French Drugs & IndustriesLimited and its associates. | Download

Lupin Limited has informed the Exchange about acquisition of a portfolio of brands (including all rights and interests associated with such products) of Anglo-French Drugs & IndustriesLimited and its associates. | Download

Cash Dividend 
Ex. DateJul 27, 2021

Final • Div/Share: ₹ 6.5

See all events